Search

for
Search:

Learn

0 / 0 results

— no results

Research

5 / 88 results

research Molecular Docking Studies and ADME-Tox Prediction of Phytocompounds from Merremia Peltata as a Potential Anti-Alopecia Treatment

7 citations, April 2021 in “Journal of advanced pharmaceutical technology & research”

The compound 16 from the Merremia peltata plant could potentially be a good treatment for hair loss (alopecia) due to its strong activity and favorable skin absorption.

research Molecular Docking Studies and ADME Prediction of Novel Isatin Analogs with Potent Anti-EGFR Activity

15 citations, January 2014 in “Medicinal chemistry”

Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.

research Molecular Docking Studies and ADME-Tox Prediction of Phytocompounds from Punica granatum Peel as a Potential Anti-Alopecia Treatment

May 2024 in “EAS Journal of Pharmacy and Pharmacology”

Active Anti-Alopecia Chemical Identification of Merremia Peltata Leaves and Computational Study Toward Androgen Receptor Using Molecular Docking and Molecular Dynamic Simulation

research Active Anti-Alopecia Chemical Identification of Merremia Peltata Leaves and Computational Study Toward Androgen Receptor Using Molecular Docking and Molecular Dynamic Simulation

4 citations, August 2022 in “The Scientific World Journal”

Merremia peltata leaf extract, particularly the bufotalinin compound, shows potential for treating hair loss.

In Silico Analysis of Berberine as a Potential Therapeutic Approach for Various Signaling Pathways Linked to Androgenetic Alopecia

research In Silico Analysis of Berberine as a Potential Therapeutic Approach for Various Signaling Pathways Linked to Androgenetic Alopecia

July 2024 in “Recent Advances in Inflammation & Allergy Drug Discovery”

Berberine may be a safe and effective treatment for male pattern baldness.

View more "adme" in research →

Community Join

1 / 1 results

community FCE 28260: A Forgotten 5α-Reductase Inhibitor

in Research 330 upvotes 3 months ago

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.